{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
CareDx, Inc. Hits New 52-Week High of $26.26, Up 75.47%
CareDx, Inc. has achieved a new 52-week high, reflecting a strong performance with a 75.47% increase over the past year. The company reported significant growth in operating profit and cash flow, maintaining positive results for three consecutive quarters, and showcasing a solid financial position with a favorable valuation.
CareDx, Inc. Hits New 52-Week High of $24.82, Up 55.83%
CareDx, Inc. has achieved a new 52-week high, reflecting its strong performance with a one-year growth of 55.83%. The company reported significant operating profit growth and positive results over three consecutive quarters, showcasing robust financial metrics and solidifying its market position with a market capitalization of USD 859 million.
CareDx, Inc. Hits New 52-Week High of $24.12, Surges 61.39%
CareDx, Inc. has achieved a new 52-week high, reflecting a strong performance with a significant increase over the past year. The company reported impressive financial metrics, including substantial growth in operating profit and cash flow, while maintaining a high market capitalization and institutional holdings.
CareDx, Inc. Hits New 52-Week High of $24.11, Up 58.58%
CareDx, Inc. has achieved a new 52-week high, reflecting its strong performance with a 58.58% increase over the past year. The company reported significant growth in operating profit and cash flow, alongside impressive net profit increases. With a market cap of USD 859 million, it enjoys high institutional investor confidence.
CareDx, Inc. Hits New 52-Week High of $23.10, Reflecting Strong Growth
CareDx, Inc. has achieved a new 52-week high, reflecting strong performance with a notable one-year growth rate. The company reported substantial increases in operating profit and cash flow, alongside impressive growth in pre-tax and net profits. Its market capitalization and high institutional holdings indicate robust financial health and investor confidence.
Is CareDx, Inc. overvalued or undervalued?
As of October 17, 2025, CareDx, Inc. is considered very attractive and undervalued despite negative earnings, with a Price to Book Value of 2.87 and an EV to Sales ratio of 2.49, while its stock has significantly underperformed compared to the S&P 500.
Is CareDx, Inc. overvalued or undervalued?
As of October 17, 2025, CareDx, Inc. has improved its valuation outlook to very attractive, appearing undervalued with favorable metrics compared to peers, despite its current loss-making status.
Is CareDx, Inc. overvalued or undervalued?
As of October 17, 2025, CareDx, Inc. is considered very attractive in valuation despite being loss-making, with a Price to Book Value of 2.87 and an EV to Capital Employed ratio of 5.58, while underperforming the S&P 500 with a year-to-date return of -32.70%.
CareDx, Inc. Experiences Revision in Stock Evaluation Amid Challenging Financial Metrics
CareDx, Inc., a microcap in the Pharmaceuticals & Biotechnology sector, is facing financial challenges, evidenced by its negative P/E ratio and low ROCE and ROE. The company's stock performance has been volatile, with a year-to-date return significantly lower than the S&P 500, highlighting a competitive landscape.
Is CareDx, Inc. overvalued or undervalued?
As of October 10, 2025, CareDx, Inc. has a valuation grade of "very attractive" despite being overvalued with a Price to Book Value of 2.87 and a negative EV to EBIT ratio of -27.94, while its stock has declined by 52.87% over the past year, underperforming the S&P 500's 13.36% gain.
CareDx, Inc. Experiences Revision in Stock Evaluation Amidst Challenging Market Conditions
CareDx, Inc. has experienced a valuation adjustment amid operational challenges, reflected in its financial metrics. The company reports a Price to Book Value of 2.87 and significant declines in stock performance, with a year-to-date drop of 31.85%. Comparatively, its peers show stronger valuation metrics and operational efficiency.
Is CareDx, Inc. technically bullish or bearish?
As of September 2, 2025, CareDx, Inc. has shifted to a bearish trend with weak strength indicators, underperforming the S&P 500 with a 1-year return of -49.52% compared to its 17.14%.
Is CareDx, Inc. overvalued or undervalued?
As of July 7, 2025, CareDx, Inc. is considered undervalued with a price of 14.77, significantly lower than its 52-week high of 32.97, and despite a 49.52% decline over the past year, its valuation ratios suggest potential for growth compared to peers like Organogenesis and Castle Biosciences.
Is CareDx, Inc. overvalued or undervalued?
As of February 26, 2025, CareDx, Inc. is considered very attractive and undervalued at $18.95, with a significant improvement in valuation despite a negative ROCE of -19.95% and a negative P/E ratio of -58.59%, outperforming the S&P 500 with a 34.78% return over the past year.
Is CareDx, Inc. technically bullish or bearish?
As of June 18, 2025, the market trend is neutral with mixed signals: weekly indicators show mild bullishness while monthly indicators are mildly bearish, indicating a lack of strong directional momentum.
Who are in the management team of CareDx, Inc.?
As of March 2022, the management team of CareDx, Inc. includes Dr. Peter Maag (Executive Chairman), Dr. Reginald Seeto (CEO), and several independent directors, including Mr. Michael Goldberg, Mr. George Bickerstaff, Dr. Frederick Cohen, Dr. Grace Colon, and Ms. Christine Cournoyer. They collectively guide the company's strategic direction.
What does CareDx, Inc. do?
CareDx, Inc. is a molecular diagnostics company specializing in diagnostic surveillance solutions for transplant patients, with recent net sales of $85 million and a market cap of approximately $1.09 billion. The company reported a net profit loss of $10 million as of March 2025.
How big is CareDx, Inc.?
As of Jun 18, CareDx, Inc. has a market capitalization of $1.09 billion, with net sales of $346.42 million and a net profit of $68.55 million over the latest four quarters.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
